Meta-analysis of the prognostic value of circulating tumor cells in breast cancer
- PMID: 22908097
- DOI: 10.1158/1078-0432.CCR-12-1587
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer
Abstract
Purpose: The prognostic value of circulating tumor cells (CTC) detected in breast cancer patients is currently under debate. Different time points of blood collections and various CTC assays have been used in the past decades. Here, we conducted the first comprehensive meta-analysis of published literature on the prognostic relevance of CTC, including patients with early and advanced disease.
Experimental design: A comprehensive search for articles published between January 1990 and January 2012 was conducted; reviews of each study were conducted and data were extracted. The main outcomes analyzed were overall survival (OS) and disease-free survival (DFS) in early-stage breast cancer patients, as well as progression-free survival (PFS) and OS in metastatic breast cancer patients. Pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using the random and the fixed-effects models. Subgroup and sensitivity analyses were also conducted.
Results: Forty-nine eligible studies enrolling 6,825 patients were identified. The presence of CTC was significantly associated with shorter survival in the total population. The prognostic value of CTC was significant in both early (DFS: HR, 2.86; 95% CI, 2.19-3.75; OS: HR, 2.78; 95% CI, 2.22-3.48) and metastatic breast cancer (PFS: HR, 1.78; 95% CI, 1.52-2.09; OS: HR, 2.33; 95% CI, 2.09-2.60). Further subgroup analyses showed that our results were stable irrespective of the CTC detection method and time point of blood withdrawal.
Conclusion: Our present meta-analysis indicates that the detection of CTC is a stable prognosticator in patients with early-stage and metastatic breast cancer. Further studies are required to explore the clinical utility of CTC in breast cancer.
©2012 AACR
Similar articles
-
Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors.BMC Cancer. 2023 Dec 12;23(1):1224. doi: 10.1186/s12885-023-11711-7. BMC Cancer. 2023. PMID: 38087278 Free PMC article.
-
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Nov 2;3(11):e2026921. doi: 10.1001/jamanetworkopen.2020.26921. JAMA Netw Open. 2020. PMID: 33211112 Free PMC article.
-
Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.BMC Cancer. 2017 Nov 7;17(1):725. doi: 10.1186/s12885-017-3704-8. BMC Cancer. 2017. PMID: 29115932 Free PMC article. Review.
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15. Ann Oncol. 2015. PMID: 25515656
-
The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis.Oncotarget. 2016 Jun 14;7(24):37361-37369. doi: 10.18632/oncotarget.8156. Oncotarget. 2016. PMID: 27008698 Free PMC article. Review.
Cited by
-
Comment for the "EpCAM-based Flow Cytometric Detection of Circulating Tumor Cells in Gallbladder Carcinoma Cases".Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2179. doi: 10.31557/APJCP.2020.21.8.2179. Asian Pac J Cancer Prev. 2020. PMID: 32856840 Free PMC article. No abstract available.
-
Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry.Biotechnol Lett. 2021 Jan;43(1):25-34. doi: 10.1007/s10529-020-03007-8. Epub 2020 Sep 21. Biotechnol Lett. 2021. PMID: 32959190
-
Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.Breast Cancer Res. 2013 Mar 7;15(2):R20. doi: 10.1186/bcr3395. Breast Cancer Res. 2013. PMID: 23497487 Free PMC article.
-
Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer.Cancers (Basel). 2020 Apr 24;12(4):1055. doi: 10.3390/cancers12041055. Cancers (Basel). 2020. PMID: 32344685 Free PMC article.
-
The microRNAs as prognostic biomarkers for survival in esophageal cancer: a meta-analysis.ScientificWorldJournal. 2014;2014:523979. doi: 10.1155/2014/523979. Epub 2014 Jul 6. ScientificWorldJournal. 2014. PMID: 25097879 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous